Hans-Jürgen Stellbrink

Detection of minor populations of drug-resistant HIV-1 in acute seroconverters

Hauke Walter, Stefan Fenske, H. Jessen, 2005, AIDS.

Highly active antiretroviral therapy significantly improves the prognosis of patients with HIV‐associated progressive multifocal leukoencephalopathy

H. Stellbrink, H. Albrecht, C. Eggers, 1998, AIDS.

Risk of HIV transmission through condomless sex in serodifferent gay couples with the HIV-positive partner taking suppressive antiretroviral therapy (PARTNER): final results of a multicentre, prospective, observational study

Hansjakob Furrer, Manuel Battegay, Pietro Vernazza, 2019, The Lancet.

Novel Compounds for the Treatment of HIV Type-1 Infection

H. Stellbrink, Hans-Jürgen Stellbrink, 2009, Antiviral chemistry & chemotherapy.

Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study

Clare Brennan, Carlo Torti, Mark Bloch, 2013, The Lancet.

Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia.

Christine Katlama, Joep Lange, Adriano Lazzarin, 2003, The New England journal of medicine.